Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo Indication-Specific Analgesics Slated For Mid-2001 Launch

This article was originally published in The Tan Sheet

Executive Summary

Perrigo plans to launch a Women's Menstrual Relief analgesic in April, comparable to McNeil Consumer Healthcare's Women's Tylenol, which debuted in October.

You may also be interested in...



Perrigo Boosts R&D Spending, Focuses On Quality Control

Perrigo plans to increase R&D spending in the second half of FY 2001 pending a favorable FDA follow-up manufacturing audit of the firm's Allegan, Mich. facility, President & CEO David Gibbons told analysts during a conference call Jan. 23.

Perrigo Boosts R&D Spending, Focuses On Quality Control

Perrigo plans to increase R&D spending in the second half of FY 2001 pending a favorable FDA follow-up manufacturing audit of the firm's Allegan, Mich. facility, President & CEO David Gibbons told analysts during a conference call Jan. 23.

Perrigo Boosts R&D Spending, Focuses On Quality Control

Perrigo plans to increase R&D spending in the second half of FY 2001 pending a favorable FDA follow-up manufacturing audit of the firm's Allegan, Mich. facility, President & CEO David Gibbons told analysts during a conference call Jan. 23.

Related Content

Topics

UsernamePublicRestriction

Register

PS091914

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel